Avalo Therapeutics (NASDAQ:AVTX) Shares Up 5.9% – Should You Buy?

Avalo Therapeutics, Inc. (NASDAQ:AVTX)’s share price shot up 5.9% during mid-day trading on Wednesday . The company traded as high as $20.93 and last traded at $20.90. 411,364 shares were traded during mid-day trading, a decline of 64% from the average session volume of 1,156,686 shares. The stock had previously closed at $19.74.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AVTX. BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. HC Wainwright decreased their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Guggenheim set a $48.00 target price on shares of Avalo Therapeutics and gave the stock a “buy” rating in a report on Friday, August 7th. Wedbush dropped their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.10.

Avalo Therapeutics Stock Down 2.4%

The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -4.59 and a beta of 0.80. The stock has a 50 day moving average of $18.89 and a 200 day moving average of $16.75.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, analysts predict that Avalo Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Insider Activity

In related news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider owned 51,776 shares in the company, valued at approximately $931,968. This trade represents a 2.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the third quarter valued at about $143,000. AlphaCentric Advisors LLC acquired a new stake in Avalo Therapeutics in the first quarter valued at about $174,000. California State Teachers Retirement System bought a new position in Avalo Therapeutics in the second quarter valued at about $196,000. Finally, Jump Financial LLC bought a new position in Avalo Therapeutics in the fourth quarter valued at about $238,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.